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Background: This study examined the measurement properties of the Japanese version of the European
Organisation for Research and Treatment of Cancer (EORTC) Hepatocellular Carcinoma-Specific Quality of Life
Questionnaire (QLQ-HCC18).
Methods: EORTC quality of life (QOL) translation guidelines were followed to create a Japanese version of the
EORTC QLQ-HCC18. This was then administered to 192 patients with hepatocellular carcinoma along with the
EORTC QLQ-C30 and FACT-Hep questionnaires. Tests for reliability and validity were conducted including
comparison of scores between the EORTC and FACT questionnaire and detailed assessment of the new scales and
items in clinically distinct groups of patients.
Results: Multi-trait scaling analysis confirmed three putative scales in the QLQ-HCC18, fatigue, fever and nutrition.
Cronbach’s alpha for these scales were between 0.68 and 0.78. The QLQ-HCC18 scales correlated with scales
measuring similar items in the FACT-Hep and the questionnaire was stable over time with an intra-class correlation
score of 0.70 for almost all scales. The questionnaire had the ability to distinguish between patients with different
Karnofsky Performance Status, and Child-Pugh liver function class.
Conclusions: The Japanese version of EORTC QLQ-HCC18 is a reliable supplementary measure to use with EORTC
QLQ-C30 to measure QOL in Japanese patients with hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is the most common
malignancy in the world, accounting for more than half a
million new cases annually [1,2]. The highest incidence
rates are in eastern and south-eastern Asia, western and
central Africa [2]. The incidence is low in most developed
countries, however, Japan has a very high prevalence of
HCC, and 70% are caused by hepatitis C viruses [3].
Although the 5-year survival rates of up to 60 to 70% can
be achieved in well-selected patients, the recurrence rate
remains very high [4,5]. The 5-year recurrence rate after
potentially curative liver resection is up to 80% [4-6]. In* Correspondence: naokom-tky@umin.ac.jp
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reproduction in any medium,provided the origcountries such as Japan, where cadaveric donor organs are
scarce, application of liver transplantation is limited [7,8].
Thus, most patients with HCC undergo repeated non-
transplant treatments such as surgical resection, percutan-
eous radiofrequency ablation and embolization. Although
survival data and information about the side effects of
treatment are widely available, much less is known about
how treatment for HCC impacts upon the patients’ quality
of life (QOL). Given the time course of the disease, and
the burden of repeated treatment, there are increasing
concerns about QOL associated with HCC. When decid-
ing upon treatment, consideration of QOL outcomes
could be as important as survival. However, there are no
HCC-specific QOL questionnaires in Japan.
At present, there are two disease-specific QOL question-
naires for evaluating the QOL of patients with HCC. One isral Ltd. This is an Open Access article distributed under the terms of theCreative
mmons.org/licenses/by/2.0), which permitsunrestricted use, distribution, and
inal work is properly cited.
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Cancer (EORTC) Quality of Life Group questionnaire, the
QLQ-HCC18, and the other is the Functional Assessment
of Cancer Therapy (FACT) Hepatobiliary (FACT-Hep)
questionnaire [9,10]. As they are disease-specific, they are
combined with generic questionnaires such as the QLQ-
C30 and FACT generic questionnaires, respectively, to
produce a generic and a specific QOL assessment [11,12].
The major difference between FACT-Hep and EORTC
QLQ-HCC18 is that FACT-Hep targets not only patients
with HCC but also patients with pancreatic, biliary and
metastatic liver cancer, whereas the QLQ-HCC18 is
designed specifically for patients with HCC. Currently
there is a lack of published data demonstrating the meas-
urement properties of EORTC QLQ-HCC18.
The objective of this study, therefore, was to develop a
Japanese version of EORTC QLQ-HCC18, and to validate
its measurement properties in patients with HCC.
Methods
Translation of the Japanese version of EORTC QLQ-HCC18
The EORTC guidelines for translation of the QLQ-HCC18
was followed and authorized by the EORTC [13]. This
included a forward/backward translation of EORTC QLQ-
HCC18. The original English version was translated into
Japanese by two independent translators who were native
Japanese speakers with proficiency in English. The research
coordinator compared the two forward translations and
checked them for any discrepancies. The discrepancies
between the two translations were discussed with the trans-
lators until we agreed on one provisional forward transla-
tion. This forward translation was then back translated into
English by two independent translators who were native
speakers of English with proficiency in Japanese. The
English back translations and the original English version
were compared to assure that there were no differences in
the meaning of the questions in the questionnaires. The
provisional Japanese version was pilot tested on 10 patients
diagnosed with HCC who had satisfied the following eligi-
bility criteria: (1) age> 20 years; (2) ability to communicate
in Japanese; (3) ability to participate in this study, as judged
by an attending doctor; (4) confirmation of medical diagno-
sis; (5) no other concurrent malignancy; and (6) consent to
participate in this study. The pilot test was conducted
according to the manual provided by EORTC [13] as
of June 2008. The average time necessary for complet-
ing the QLQ-HCC18 was less than 5 minutes and the
questionnaire was well understandable and acceptable
in most patients. Results of the translation and the
pilot study were reviewed by the EORTC translation
coordinator and the original author of QLQ-HCC18,
to ensure the content and applicability was main-
tained, and the EORTC QLQ-HCC18 Japanese version
was authorized by the EORTC Quality of Life Group.The Japanese version of EORTC QLQ-HCC18 was
used in this validation study.
Data collection
This study recruited 200 patients diagnosed with HCC at
The University of Tokyo Hospital, one of the largest referral
centers for treatment of HCC in Japan, and written consent
was obtained. Patients were recruited between July 2008
and November 2008. The eligibility criteria were the same
as for pilot testing. Patients completed each of the three
questionnaires: EORTC QLQ-C30, QLQ-HCC18, and
FACT-Hep, and a questionnaire about demographic charac-
teristics. To confirm test-retest reliability of the Japanese
version of QLQ-HCC18, patients with stable disease were
invited to complete QLQ-HCC18 for a second time after
two weeks. Medical data were collected by review of med-
ical care records. The researcher checked for absent
responses after receiving the questionnaire and wherever
possible asked the patients to respond to the missing items.
This study was conducted with the approval of the ethics
committee of The University of Tokyo.
Measurements
The EORTC QLQ-C30 core questionnaire (version 3.0) is
a generic QOL measure for cancer patients, and comprises
a global health status/QOL scale, five multi-item func-
tional scales, three multi-item symptom scales and single
items for the assessment of symptoms and the financial
impact of disease and treatment [11]. The reliability and
validity of the Japanese version of the EORTC QLQ-C30
has been demonstrated [14].
EORTC QLQ-HCC18 is an 18-item HCC-specific supple-
mental module developed to augment QLQ-C30 and to en-
hance the sensitivity and specificity of HCC-related QOL
issues [9]. EORTC QLQ-HCC18 was developed in four
stages on the basis of the EORTC guidelines for scale devel-
opment [9]. Briefly, items were created during phase one
after conducting a literature review and interviewing 32
patients with HCC from four different countries as well as
10 health professionals. In phase two, a preliminary ques-
tionnaire was constructed using the EORTC item bank as a
reference. In phase three, a pretest was administered to 158
patients with HCC from three countries to examine recep-
tivity and relevance. The original questionnaire is from the
end of phase three. The hypothesized scale structure and
single items address aspects of chronic liver disease
(nutrition, jaundice, fever, abdominal swelling), as well as
QOL issues specific to the primary tumor and its treatment
(fatigue, body image, pain).
The original English version contains six multi-item
scales addressing fatigue, body image, jaundice, nutrition,
pain and fever, as well as two single items addressing
sexual life and abdominal swelling. The scales and items
are linearly transformed to a 0 to 100 score, where 100
Table 1 Socio-demographic and clinical characteristics of
the study subjects (n = 192)
Male gender 122 (63.5)
Age, y* 68.1 (8.5)
Employed full time or part-time 77 (40.1)
Post compulsory education or above 155 (80.7)




Hepatitis C virus 126 (65.6)
Hepatitis B virus 38 (19.8)






Stage I / II 161 (83.9)
Stage III / IV 31 (16.1)
Time since diagnosis, month* 39.6 (34.5)
Past medical history†
Hepatectomy 48 (25.0)
Percutaneous ablation 137 (71.4)
Chemoembolization 64 (33.3)
Systemic therapy 1 (0.5)
No medical history 13 (6.8)
Values are numbers (%) otherwise specified. * Data was expressed as mean
(standard deviation). † Some patients underwent multiple treatments.
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(the phase 4 part of questionnaire development) is
currently being conducted to examine the validity and
reliability of the scores in several countries.
The reliability and validity of the original version of
FACT-Hep, another hepatobiliary cancer-specific scale, has
been demonstrated [10]. FACT-Hep is a 45-item self-report
instrument that comprises 27 FACT General (FACT-G)
items and an 18-item hepatobiliary subscale. The Japanese
version of the 18-item hepatobiliary subscale was used in
this study as a comparison instrument. All items are scored
from 0 to 4, with higher scores indicating better QOL.
Data analysis
Multi-trait scaling analyses [15] evaluated the scale struc-
tures of QLQ-HCC18. This technique is used to test for
item convergent and discriminant validity, and is based on
the examination of item-scale correlations. The Pearson
correlations of an item with its own scale (corrected for
overlap) and other scales were calculated. Evidence of item
convergent validity was defined as a correlation above 0.40
with its own scale. Evidence of item discriminant validity
was based on a comparison of correlation of an item with
its own scale and with other scales. Scaling success for any
scale is defined as the number of convergent correlation
coefficients significantly higher than the discriminant correl-
ation coefficient divided by the total number of correlations.
The mean scale and item scores were also calculated, and a
frequency analysis was performed.
The following psychometric aspects were assessed: reli-
ability, i.e., internal consistency and test-retest reliability;
validity: known group comparison, and correlation analyses
with the FACT-Hep.
The internal consistency reliability of the multi-item
questionnaire scales was assessed by Cronbach’s alpha co-
efficient. Preferable reliability was indicated by coefficient
greater than 0.70. The test-retest reliability of the scales
and single items was assessed by the intra-class correlation
coefficient. Scale discriminant validity (clinical validity)
was tested by known group comparisons to assess whether
the questionnaire scores were able to discriminate between
subgroups of patients differing in clinical status by using
the Student t-test. The Karnofsky Performance Status
(KPS) and Child-Pugh grade for clinical parameters were
employed to form mutually exclusive patient subgroups.
Higher scores in KPS signify better performance status.
Liver function becomes worse in alphabetical order of
Child-Pugh grade A, B, C. We hypothesized that scores of
QLQ-HCC18 are low in patients with better performance
status (KPS 80–100) and better liver function (Child-Pugh
class A). Convergent validity was tested first by multi-trait
analyses, and we then conducted another convergent valid-
ity test by correlation analyses with FACT-Hep. Pearson’s
correlation coefficient was used to examine the correlationbetween similar items in FACT-Hep and QLQ-HCC18. We
hypothesized that if Pearson’s correlation coefficients were
more than 0.40 between scales, they were conceptually
related. P< 0.05 was considered as statistically significant.
Statistical analyses were performed using SAS software
(SAS for Windows, release 9.1; SAS Institute Inc., Cary NC,
USA).Results
Participants
Responses were obtained from 192 patients (eight non
responders), and 139 completed the test-retest question-
naire two weeks after the first assessment.
Socio-demographic and clinical characteristics at baseline
are shown in Table 1. Most patients were male (64.1%), had
good performance status (86.5%) and had good liver func-
tion (66.2%).
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We initially performed multi-trait scaling analyses for the
putative scale structure, and the results showed that the ori-
ginal two-item scale of body image and jaundice had low
convergent and discriminant validity. After discussion with
the original author of QLQ-HCC18 (JMB) we decided to
split the scale into single items. The tests were then per-
formed on the remaining scales and four single items.
Results of the multi-trait scaling analyses are shown in
Table 2. A summary of the multi-trait scaling analysis and
internal consistency is shown in Table 3. The convergent
correlation coefficient of the scales for fatigue, nutrition and
fever varied from 0.23 to 0.75, and the scaling success rate
ranged from 87% to 100%. Cronbach’s alpha coefficient of
these scales was satisfactory, ranging from 0.68 to 0.78. The
convergent correlation coefficient of the scales for pain was
0.25, and the scaling success rate was 50%. Cronbach’s alpha
coefficient of this scale was 0.37.
The results of the descriptive statistics of the putative
scales/single items and test-retest reliability on the ques-
tionnaire are shown in Table 4. The intra-class correlation
coefficients of the scales varied between 0.67 and 0.88.
Ninety-four percent of the patients answered ‘not at all’ to
item 36, which asked patients whether they were concerned
by their skin or eyes being yellow. Responses to item 48,
which asked about sexual function, were missing in seven
patients (3.6%).
Results of the known group comparisons are shown in
Table 5. Patients with poorer performance status (KPS ofTable 2 Item-scale correlations for multi-trait scaling analyses
Item
Fatigue
Item46 Have you been less active than you would like to be?
Item45 Have you found it difficult to keep going or to finish things you
Item47 Have you needed to sleep during the day?
Nutrition
Item31 Did you feel thirsty?
Item32 Have you had problems with your sense of taste?
Item42 Have you worried about getting enough nourishment?
Item43 Have you felt full up too quickly after beginning to eat?
Item44 Have you worried about your weight being too low?
Pain
Item38 Have you had pain in your shoulder?
Item39 Have you had abdominal pain?
Fever
Item40 Have you had fevers?
Item41 Have you had chills?
Correlations marked † were corrected for overlap.70 or lower) reported significantly higher (worse) scores
for all scales except for abdominal swelling and sexual
interest than those with better performance status (KPS
of 80–100). Patients with worse liver disease (Child-Pugh
classes B and C) reported significantly higher (worse)
scores for all scales except for body image and pain than
those with better liver function (Child-Pugh class A).
Results of convergent validity are shown in Table 6. The
QLQ-HCC18 Japanese version scales had an acceptable
correlation (coefficient value over 0.40) with similar items
in FACT-Hep except for items of weight loss, appetite and
activity.
Discussion
This study describes psychometric testing of the Japanese
version of the QLQ-HCC18 questionnaire, which is an
HCC-specific module of EORTC QLQ-C30. The overall
results show that this questionnaire is reliable and has
acceptable measurement properties for use with the
QLQ-C30 to assess health-related QOL in Japanese
patients with HCC.
Assessment of QOL in cancer patients is optimally per-
formed with a combination of a generic questionnaire and
a disease-specific questionnaire to ensure that common
problems are uniformly detected and reported as well as
specific issues related to disease site and treatment. This
framework for QOL assessment has been adopted and
popularized by the EORTC Quality of Life Group and the
Functional Assessment of Chronic Illness Therapyof the EORTC QLQ-HCC18
Hypothesized scales of the EORTC QLQ-HCC18†
Fatigue Nutrition Pain Fever
0.68† 0.57 0.29 0.32
started? 0.75† 0.55 0.32 0.35
0.44† 0.29 0.24 0.14
0.42 0.50† 0.30 0.23
0.30 0.50† 0.18 0.18
0.45 0.54† 0.31 0.51
0.48 0.44† 0.30 0.27
0.21 0.23† 0.04 0.28
0.20 0.15 0.25† 0.11
0.39 0.48 0.25† 0.36
0.34 0.46 0.27 0.52†
0.23 0.31 0.19 0.52†
Table 3 Convergent and discriminant validity and internal consistency reliability for the EORTC QLQ-HCC18












Fatigue 3 0.44-0.75 0.14-0.57 9/9 100 0.78
Nutrition 5 0.23-0.54 0.04-0.51 13/15 87 0.68
Pain 2 0.25 0.11-0.48 3/6 50 0.37
Fever 2 0.52 0.15-0.46 6/6 100 0.68
† Number of convergent correlations significantly higher than discriminant correlations divided by total number of correlations.
{ Scaling success rate is the previous column as a percentage.
Table 4 Descriptive statistics of the EORTC QLQ-C30 and
the QLQ-HCC18 and test-retest reliability
Scale Score* Intraclass correlation coefficient†
The QLQ-HCC18
Scales{
Fatigue 25.6 ± 22.2 0.82
Nutrition 12.7 ± 14.1 0.88
Pain 13.5 ± 17.1 0.80
Fever 5.3 ± 12.9 0.67
Single items
Body Image 1 (item33) 34.0 ± 31.9 0.73
Body Image 2 (item35) 21.1 ± 27.7 0.70
Jaundice 1 (item36) 2.77 ± 2.45 0.79
Jaundice 2 (item37) 22.2 ± 27.4 0.82
Abdominal Swelling 15.8 ± 23.6 0.78
Sexual Interest 12.6 ± 25.2} 0.77‖
The QLQ-C30
Scales
Physical} 84.9 ± 16.9 -
Role} 84.1 ± 22.3 -
Cognitive} 84.2 ± 17.0 -
Emotional} 79.6 ± 20.5 -
Social} 86.1 ± 20.6 -
Global QOL} 66.5 ± 21.63 -
Fatigue{ 30.9 ± 21.5 -
Nausea/Vomiting{ 1.74 ± 6.4 -
Pain{ 12.8 ± 20.6 -
Single items{
Dyspnea 15.8 ± 21.6 -
Sleep Disturbance 21.5 ± 27.5 -
Appetite Loss 12.7 ± 22.5 -
Constipation 14.2 ± 23.9 -
Diarrhea 7.81 ± 16.4 -
Financial Impact 14.6 ± 23.3 -
Data were expressed as mean ± standard deviation. * Score range 0 to 100. †
Data were assessed in 130 patients. {Higher score indicates lower QOL. } Data
were assessed in 185 patients. ‖ Data were assessed in 127 patients. } Higher
score indicates higher QOL.
Mikoshiba et al. Health and Quality of Life Outcomes 2012, 10:58 Page 5 of 7
http://www.hqlo.com/content/10/1/58(FACIT) Organization. For patients with primary and sec-
ondary liver tumors, cholangiocarcinoma or pancreatic
cancer, the FACIT system has developed a single hepato-
biliary-pancreatic module [10]. The EORTC QOL Group
has, however, focused in more depth on the specific
clinical experiences within each disease site and therefore
developed separate modules for pancreatic, primary and
secondary liver cancer. The separate modules may be
clinically more sensitive than a single questionnaire, al-
though this has not yet been formally examined. A second
advantage of the EORTC QLQ-HCC18 is that it provides
subscale scores for different domains of functioning.
FACT-Hep generates only a total score, which may
obscure findings in particular problem areas. EORTC
QLQ-HCC18 possesses a multi-dimensional QOL assess-
ment that may be more useful for clinicians to direct ther-
apy. A final advantage of the EORTC QLQ module is that it
was specifically developed for use in international trials; a
large database will soon be available to facilitate compari-
sons across studies, and there is some assurance of cross-
cultural suitability.
In this study, we tested the reliability and validity, includ-
ing internal consistency reliability, test-retest reliability,
convergent and discriminant validity, known group com-
parison, of the Japanese version of QLQ-HCC18. In the
descriptive statistics and frequency analyses, the item asses-
sing problems related to jaundice showed low scores. This
was because few patients were jaundiced at the time of the
data collection. In addition, because the Japanese belong to
a race with a yellowish skin complexion, jaundice tends to
be masked. The results of multi-trait scaling analyses
(convergent and discriminant validity), had a good scaling
success rate and acceptable Cronbach’s alpha (internal
consistency reliability) except for the scale for pain, which
had a low scaling success rate and a low Cronbach’s alpha.
One reason for this may be because shoulder and abdom-
inal pain are not necessarily related symptoms that occur
simultaneously. Furthermore, although pain scales have
been created in anticipation of pain caused by cancer treat-
ment and progression, few patients had advanced cancer.
The nutrition scale had a high rate of success. However, the
convergent validity of the item termed “concern about low
weight” was below the standard value. The nutrition scale
was assumed to involve problems caused by impaired liver
Table 5 Known group comparison of differences in mean scores of scales and items
Karnofsky Performance status score Child-Pugh grade
100-80 <80 t-test A B and C t-test
p
value
n= 166 n= 26 p value n= 127 n=65
Scales†
Fatigue 21.0 ± 17.8 54.7 ± 25.9 < 0.001 22.0 ± 20.4 32.7 ± 24.1 0.001
Nutrition 10.8 ± 11.4 24.9 ± 22.0 < 0.001 10.9 ± 12.0 16.2 ± 17.1 0.02
Pain 11.6 ± 15.7 25.6 ± 20.7 0.003 12.3 ± 17.2 15.9 ± 16.8 0.17
Fever 4.3 ± 10.2 11.5 ± 23.0 0.003 3.5 ± 9.1 8.7 ± 17.7 0.02
Single items†
Body Image 1(item33) 30.7 ± 29.6 55.1 ± 38.8 0.004 29.7 ± 30.3 42.6 ± 33.6 0.01
Body Image 2 (item35) 19.5 ± 26.5 32.1 ± 33.3 0.03 19.7 ± 25.3 24.1 ± 32.0 0.34
Jaundice 1 (item36) 1.2 ± 6.2 12.8 ± 28.4 0.04 0.8 ± 5.1 6.7 ± 19.7 0.02
Jaundice 2 (item37) 17.7 ± 23.4 51.3 ± 33.0 < 0.001 16.5 ± 23.7 33.3 ± 30.6 0.002
Abdominal swelling 14.1 ± 21.2 27.0 ± 34.0 0.07 13.1 ± 21.5 21.0 ± 26.7 0.04
Sexual interest 12.0 ± 24.1{ 16.7 ± 31.6 0.47 9.3 ± 21.1} 19.0 ± 30.9‖ 0.03
Data were expressed as mean ± standard deviation unless otherwise specified. * p< 0.05, †Higher score indicates worse QOL
{ missing in 7, } missing in 5, ‖ missing in 2.
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been affected by cancer progression. Patients included in
the original article and patients in this study had almost
identical liver function, but the extent of cancer progression
differed, and many of our patients had cancer that was
detected at an earlier stage. The results of test-retest reliabil-
ity showed good intra-class correlation coefficients for most
scales. Results of known group comparisons showed that
the module had the ability to assess differences between
groups with different clinical characteristics in almost all of









Fatigue 0.33 0.26 0.2 0.42* 0.59*
Body Image 1
(item33)
0.31 0.32 −1.7 0.46* −0.08
Body Image 2
(item35)
0.39 0.01 −0.05 0.4* 0.1
Jaundice 1
(item36)
0.25 0.19 −0.07 0.2 −0.13
Jaundice 2
(item37)
0.25 0.05 −0.05 0.31 0.45
Nutrition 0.32 0.34 0.31 0.32 0.38
Pain 0.32 0.11 0.14 0.28 0.32
Fever 0.25 0.26 0.13 0.18 0.25
Abdominal
Swelling
0.43* 0.07 0.03 0.16 0.29
Sexual Interest
{
0.26 0.14 −0.06 0.25 0.24
* indicates Pearson’s correlation coefficient larger than 0.4, _Underline indicates a p
assessed in 185 patients.confirmed good correlations between the groups for most
scales/single items in the two questionnaires (QLQ-HCC18
and FACT-Hep). However, correlations between items of
weight loss, appetite, and activity in FACT-Hep and corre-
sponding scales in QLQ-HCC18 were low. This may have
occurred because of the reverse scoring used in appetite
and activity items in FACT-Hep which may have led to
confusion.
While the results show the Japanese version of EORTC
QLQ-HCC18 is a reliable instrument, some caution is
necessary. First, these results on the QLQ-HCC18 aree QLQ-HCC18 and the FACT-Hep
e FACT-Hep
Activity† Jaundice Fever Itching Taste Chill Thirsty Abdominal
Pain
0.26 0.26 0.3 0.43* 0.32 0.17 0.37 0.42*
0.17 0.3 0.3 0.25 0.25 0.23 0.45 0.38
0.07 0.18 0.31 0.2 0.3 0.12 0.23 0.47
0.73 0.53* 0.3 0.12 0.18 0.56 0.28 0.3
−0.01 0.18 0.28 0.83* 0.33 0.26 0.35 0.37
0.23 0.31 0.28 0.26 0.44* 0.23 0.68* 0.33
0.14 0.21 0.26 0.34 0.15 0.2 0.3 0.40*
0.09 0.29 0.72* 0.35 0.18 0.61* 0.22 0.27
0.06 0.23 0.3 0.3 0.15 0.28 0.24 0.42*
0.08 0.06 0.12 0.12 0.06 0.12 0.13 0.24
air of scales that should correlate theoretically, † Reverse scoring, { Data were
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tution using the Japanese version, few patients with se-
vere cirrhosis or advanced disease were recruited, and no
patient had undergone liver transplantation, which may
limit the generalizability of the findings.
Second, this study did not address longitudinal construct
validity and responsiveness for clinical validity. In future
work, the Japanese version of EORTC QLQ-HCC18 should
be performed in multicenter facilities to confirm the
generalizability of the findings and to increase the number
of liver transplantation groups and more severely ill patients.
Furthermore, testing the sensitivity of the instrument to
changes over time is needed to evaluate treatment effects.
There are currently a variety of treatment options for
patients with HCC. Molecular targeted therapy for HCC
has recently been introduced [16], and this will lead to
increased demand for evaluating the QOL in more detail.
In addition, Japanese patients with HCC are older than
in other countries, which make the Japanese version of
QLQ-HCC18 particularly valuable because treatment
effects on QOL are more important in older patients.
Conclusion
This study showed that the Japanese version of the EORTC
QLQ-HCC18 demonstrated evidence for the measurement
properties of the questionnaire. These results suggest that it
would be a reliable instrument for measuring QOL in
patients with HCC in Japan.
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